Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a front-line drug for the treatment of type 2 diabetes, and several studies have shown that diabetes patients treated with metformin have reduced incidence of cancer. This study aimed to define the effect of metformin on CML cells to determine whether metformin overcomes nilotinib resistance, and to identify novel targets for the treatment of nilotinib resistance. Methods: We observed the effects of metformin and nilotinib on K562 and KU812 human CML cell lines. Nilotinib-resistant CML cell lines were generated by exposing cells to gradually increasing doses of nilotinib. Then, we investigated the driving force that makes resistance to nilotinib and the effect of metformin on the driving force. Results: Sub-toxic doses of metformin enhanced nilotinib efficacy by reducing Bcl-xL expression, which induces apoptosis in CML cells. Next, we generated nilotinib-resistant K562 and KU812 cell lines that overexpressed the c-Jun N-terminal kinase (JNK) gene. JNK silencing by a JNK inhibitor restored sensitivity to nilotinib. Furthermore, metformin was effective in decreasing phosphorylated JNK levels, restoring nilotinib sensitivity. Combined treatment with nilotinib and metformin was more effective than combined treatment with nilotinib and a JNK inhibitor in terms of cell proliferation inhibition. Conclusions: This study suggested that combination therapy with metformin and nilotinib may have clinical benefits of enhancing antileukemia efficacy and overcoming resistance to nilotinib.
Abstract
Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a front-line drug for the treatment of type 2 diabetes, and several studies have shown that diabetes patients treated with metformin have reduced incidence of cancer. This study aimed to define the effect of metformin on CML cells to determine whether metformin overcomes nilotinib resistance, and to identify novel targets for the treatment of nilotinib resistance. Methods: We observed the effects of metformin and nilotinib on K562 and KU812 human CML cell lines. Nilotinib-resistant CML cell lines were generated by exposing cells to gradually increasing doses of nilotinib. Then, we investigated the driving force that makes resistance to nilotinib and the effect of metformin on the driving force. Results: Sub-toxic doses of metformin enhanced nilotinib efficacy by reducing Bcl-xL expression, which induces apoptosis in CML cells. Next, we generated nilotinib-resistant K562 and KU812 cell lines that overexpressed the c-Jun N-terminal kinase (JNK) gene. JNK silencing by a JNK inhibitor restored sensitivity to nilotinib. Furthermore, metformin was effective in decreasing phosphorylated JNK levels, restoring nilotinib sensitivity. Combined treatment with nilotinib and metformin was more effective than combined treatment with nilotinib and a JNK inhibitor in terms of cell proliferation inhibition. Conclusions: This study suggested that combination therapy with metformin and nilotinib may have clinical benefits of enhancing antileukemia efficacy and overcoming resistance to nilotinib.
참고문헌 (27)
- Rowley JD, "Chromosome abnormalities in malignant hematologic diseases", Adv Cancer Res, 36, pp.103~148 (1982)
- Groffen J, "Oncogene activation by chromosomal translocation in chronic myelocytic leukemia", Cold Spring Harb Symp Quant Biol, 51(Pt 2), pp.911~921 (1986)
- Deininger MW, "The molecular biology of chronic myeloid leukemia", Blood, 96, pp.3343~3356 (2000)
- Kantarjian H, "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL", N Engl J Med, 354, pp.2542~2551 (2006)
- Franklin M, "Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as firstor second-line therapy for chronic myelogenous leukemia in the US", Curr Med Res Opin, 34, pp.353~360 (2018)
- Dae Sik Kim, "Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells", The Korean Journal of Internal Medicine, 31(2), pp.357~366 (2016), 대한내과학회[DOI]
- Ding J, "Inhibition of PI3K", mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2, 2013, pp.8, e83510~
- Fan C, "Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer", Int J Mol Med, 36, pp.204~214 (2015)
- Decensi A, "Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis", Cancer Prev Res (Phila), 3, pp.1451~1461 (2010)
- Chen G, "Metformin inhibits gastric cancer via the inhibition of HIF1α", PKM2 signaling, 2015, pp.5, 1423~1434
- Kim NY, "Metformin targets Axl and Tyro3receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells", Int J Oncol, 47, pp.353~360 (2015)
- Peng M, "Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk", Sci Rep, 6, pp.28611~ (2016)
- 이재련, "Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells", 발생과 생식, 21(2), pp.139~150 (2017), 한국발생생물학회
- Chen H, "Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes", Cancer Lett, 369, pp.97~102 (2015)
- Shi P, "Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation", Cell Discov, 3, pp.17010~ (2017)
- Xue C, "Targeting P-glycoprotein function, p53 and energy metabolism : combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7", Dox cells to doxorubicin, 2017, pp.8, 8622~8632
- Wu W, "Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription", World J Hepatol, 8, pp.985~993 (2016)
- Hughes T, "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase", J Clin Oncol, 27, pp.4204~4210 (2009)
- Saglio G, "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia", N Engl J Med, 362, pp.2251~2259 (2010)
- Camgoz A, "Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance", Leuk Lymphoma, 54, pp.1279~1287 (2013)
- Mahon FX, "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression", Cancer Res, 68, pp.9809~9816 (2008)
- Dhillon AS, "MAP kinase signalling pathways in cancer", Oncogene, 26, pp.3279~3290 (2007)
- Zhou YY, "MAPK", JNK signalling : a potential autophagy regulation pathway, 2015, pp.35, e00199~
- Mizukami Y, "A novel mechanism of JNK1 activation. Nuclear translocation and activation of JNK1 during ischemia and reperfusion", J Biol Chem, 272, pp.16657~16662 (1997)
- Messoussi A, "Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents", Chem Biol, 21, pp.1433~1443 (2014)
- Gioia R, "Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells", Blood, 118, pp.2211~2221 (2011)
- Hsieh SC, "Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK", JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression, 2014, pp.46, 2809~2822